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Unbalanced t(2;19) and t(2;16) in a neurofibromaNeurofibromas are a benign heterogeneous group of
tumors arising from peripheral nerve sheaths; they consist
of a mixture of Schwann cells, fibroblasts, perineural cells,
neuronal processes, and mast cells. Neurofibromas may
present as dermal (cutaneous or subcutaneous) or plexiform
(diffuse growths, spinal tumors, nodular or diffuse) tumors.
They may present as isolated sporadic tumors in the general
population or occur as a part of an autosomal dominant
tumor diathesis in von Recklinghausen neurofibromatosis
type 1 (NF1). Malignant transformation of neurofibromas
gives rise to nerve sheath tumors (MPNSTs) and neurofibro-
sarcoma in NF1 patients [1]. Although the genetic basis of
neurofibromas associated with NF1 has been well estab-
lished, similar genetic basis of sporadic neurofibromas is
poorly understood [2]. Loss of both alleles of NF1 occurs in
MPNSTs and associated tumors [3], but such evidence
in benign neurofibromas is lacking. Loss of heterozygosity
(LOH) at the NF1 locus has been detected in a minority of
dermal neurofibromas of NF1 syndrome [2]; however, no
such evidence exists in sporadic neurofibromas. Thus, these
findings suggest that sporadic neurofibromas may arise
through a mechanism different from that of NF1 tumors and
the understanding of the genetic mechanisms that underlie
tumorigenesis remains elusive.
At the cytogenetic level, only five cases of neurofibroma
with karyotype abnormalities have been reported [4]. These
studies did not identify any nonrandom chromosome aberra-
tions in this tumor type. We report a case of neurofibroma with
unbalanced translocations involving chromosomes 2, 16, and
19 and discuss the possible significance of these changes.
The patient is a 63-year-old woman who was evaluated
for a 3.5-cm mass in her right axilla. At surgery, a well-
circumscribed lobulated mass was excised without techni-
cal difficulty. Histologic examination revealed a uniformly
low-cellularity tumor composed of bland spindled cells with-
out nuclear pleomorphism or mitotic activity. These cells
were amidst areas of jumbled collagen and stromal mucin.
The tumor was generally encapsulated, although focal infil-
tration of adipose tissue was seen. Immunohistochemistry
was positive for S100 in the thin spindled cells. These find-
ings are diagnostic of an intramural neurofibroma, clinical
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oi:10.1016/j.cancergencyto.2003.12.005Fresh tumor tissue obtained for cytogenetic analysis was
dissociated with collagenase and grown in short-term culture
in complete RPMI medium supplemented with insulin–
transferrin–sodium selenate. Metaphase preparations, made
using standard methods, were analyzed on G-banded prepa-
rations. Twenty-two metaphases were analyzed and the
karyotype was described according to standard International
System for Human Cytogenetic Nomenclature (ISCN 1995)
[5]. Spectral karyotype (SKY) analysis was performed on
metaphase preparations using a human SKYPaint kit (Ap-
plied Spectral Imaging, Carlsbad, CA) according to manu-
facturer’s protocol. SKY images were acquired with a SD200
Spectra cube mounted on a Nikon Eclipse 800 microscope
equipped with a SKY optical filter (Chroma Technology,
Brattleboro, VT); the images were analyzed using SkyView
software (Applied Spectral Imaging). Fluorescence in situ
hybridization (FISH) was performed using whole-chromo-
some paint probes WCP 2, WCP 16, and WCP 19 (Vysis,
Downers Grove, IL) and standard hybridization methods.
Hybridization signals were analyzed using a Nikon Eclipse
600 microscope attached to a CytoVision imaging system
(Applied Imaging, Santa Clara, CA).
In the present case, a combination of G-banding, SKY,
and chromosome painting identified the karyotype as:
46,XX,der(2)t(2;19)(p25;p13.2),der(16)t(2;16)(p25;q24),
del(19)(p13.2)[22] (Fig. 1; Table 1). The SKY analysis fol-
lowed by chromosome painting allowed us to identify the
derivative chromosomes precisely.
Cytogenetic abnormalities have been reported in only five
cases of neurofibroma with clonal changes, but without any
recurrent chromosomal aberrations (Table 1). Comparative
genomic hybridization (CGH) studies showed that chromo-
some 22 losses predominate in both sporadic and NF1-
associated neurofibromas [6,7]. Most notably, losses of 17,
19p13.2, and 22q (22q12~qter) losses predominate in both
sporadic and NF1-associated neurofibromas [7]. A minimal
deletion on 19 was reported at 19p13.2~p 13.3, which was
observed more frequently in NF1-associated neurofibro-
mas than in the sporadic cases. It has been suggested that
a candidate tumor suppressor gene maps to this locus on
chromosome 19 [7].
In the present case, we found unbalanced translocations
der(2)t(2;19)(p25;p13.2) and der(16)t(2;16)(p25;q24). The
Letter to the editor / Cancer Genetics and Cytogenetics 152 (2004) 169–171170Fig. 1. Karyotype analysis of the neurofibroma. (A) G-banded karyotype showing 46,XX,der(2)t(2;19)(p25;p13.2),der(16)t(2;16)(p25;q24),del(19)(p13.2).
(B) SKY karyotype showing the same abnormalities. Arrows indicate derivative chromosomes.breakpoint on 19p13.2 is at the same region of loss found
with CGH in NF1-associated neurofibromas [7]. Based on our
karyotype, however, it is unlikely that there is a net loss ofgenetic material on 19p. The effect of the structural abnormal-
ity at 19p13.2 in activating or inactivating genes of impor-
tance to neurofibroma in the present case remains unknown.Table 1
Karyotypes of neurofibromas reported in the literature and the present case
Case no. Site Karyotype Reference
1 Spinal cord 45,XX,22 Chadduck et al., 1991–1992 [9]
2 Nasopharynx 47,XY,der(?)t(?;12)(?;q15) Mertens et al., 2000 [10]
3 Soft tissue 45~46,XX,t(1;17)(q21;q21),r(3;?)(p25q29;?), Molenaar et al., 1997 [11]
add(5)(q14),der(9)t(4;9)(q12;p11)ins(9;?)(p11;?),der(9)t(5;9)(q13;p13),
(15)(q22),der(?)t(?;7)(?;q11),mar
4 Soft tissue 46,X,t(X;2)(p22;q21),del(1)(q11),t(1;22)(p32;q11)c,(8)t(1;8)(q11;q2?4)/ Rey et al., 1987 [12]
46,XX,t(1;22)c,add(5)(q14),der(16)(p12)/45,XX,t(1;22)c,inv(8)(p23q12),
der(9)t(3;9)(q12;p22)del(3)(q26~q28),der(10)t(3;10)(p11;p12),del(12)(q14)
5 Soft tissue 47,XX,18 Riccardi and Elder, 1986 [13]
6 Axillary mass 46,XX,der(2)t(2;19)(p25;p13.2),der(16)t(2;16)(p25;q24),del(19)(p13.2)[22] Present case
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relevant to cell growth and proliferation, including two
related mitogen-activated protein kinase genes, MAP2K2
and MAP2K7, which play a critical role in mitogen growth
factor signal transduction, and neurturin (NRTN), a member
of the TGF-β subfamily. The NRTN gene may be more
relevant. This gene, which signals through RET and a GPI-
linked coreceptor, promotes survival of neuronal popula-
tions. A neurturin mutation has been described in a family
with Hirschsprung disease [8]. NRTN is a neuromodulator
that regulates the development of the neuromuscular syn-
apse. Thus, the molecular nature of 19p13 alterations in the
development and proliferation of neurofibromas remains to
be elucidated.
Description of the karyotypic abnormalities identified in
the present case may aid in identifying nonrandom chromo-
some changes in neurofibroma and in understanding the
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